Diagnostic vale of serum NSE, and s-100β and inflammatory markers levels in epilepsy
Diagnostic vale of serum NSE, and s-100β
Abstract
Aim:To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100β levels in patients with emergency secondary epilepsy(SE).
Methods:This was a retrospective cohort of 120 patients with SE who received Sodium valproate that compared with a group who received carbamazepine regarding different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumor necrosis factor (TNF)-α, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100β, total effective rate(TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later.
Results:There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P>0.05). The results showed that IL-2 of the Sodium valproate group (53.17±4.95 µg/L) was lower versus Carbamazepine group (62.38±4.83 µg/L) (P<0.05). The IL-8 of the Sodium valproate grouppostoperatively (26.48 ± 2.73 µg/L) was lower versus Carbamazepine group (33.54±3.39 µg/L) (P<0.05). Postoperatively, the TNF-αin Sodium valproate group (32.18±4.26 µg/L) was lower versus the Carbamazepine group (41.03±4.92 µg/L) (P<0.05). The s-100β (0.29±0.15) µg/L in the Sodium valproate group was lower versus Carbamazepine group (0.54±0.14) µg/L (P<0.05). The TER of the Sodium valproate group (93.33%) was higher versus the Carbamazepine group of 75% (P<0.05). The number of epileptic seizures 0.81±0.08 times per year in the Sodium valproate group was versus 1.23±0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53±0.22 min/time) was shorter than that in the Carbamazepine group (3.08±0.24 min/time).
Conclusion: sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.
References
2. Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. The Lancet. 2020 Feb 29;395(10225):735-48.
3. Royer J, Bernhardt BC, Larivière S, Gleichgerrcht E, Vorderwülbecke BJ, Vulliémoz S, Bonilha L. Epilepsy and brain network hubs. Epilepsia. 2022 Mar;63(3):537-50.
4. Milligan TA. Epilepsy: a clinical overview. The American Journal of Medicine. 2021 Jul 1;134(7):840-7.
5. Balestrini S, Arzimanoglou A, Blümcke I, Scheffer IE, Wiebe S, Zelano J, Walker MC. The aetiologies of epilepsy. Epileptic Disorders. 2021 Feb;23(1):1-6.
6. Asadi-Pooya AA, Brigo F, Lattanzi S, Blumcke I. Adult epilepsy. The Lancet. 2023 Jul 29;402(10399):412-24.
7. Falco-Walter J. Epilepsy—definition, classification, pathophysiology, and epidemiology. InSeminars in neurology 2020 Dec (Vol. 40, No. 06, pp. 617-623). Thieme Medical Publishers, Inc..
8. Zelano J, Holtkamp M, Agarwal N, Lattanzi S, Trinka E, Brigo F. How to diagnose and treat post‐stroke seizures and epilepsy. Epileptic Disorders. 2020 Jun;22(3):252-63.
9. Billakota S, Devinsky O, Kim KW. Why we urgently need improved epilepsy therapies for adult patients. Neuropharmacology. 2020 Jun 15;170:107855.
10. Ding D, Zhou D, Sander JW, Wang W, Li S, Hong Z. Epilepsy in China: major progress in the past two decades. The Lancet Neurology. 2021 Apr 1;20(4):316-26.
11. Dean JC, Penry JK. Valproate. InThe Medical Treatment of Epilepsy 2020 Sep 10 (pp. 265-278). CRC Press.
12. Wu C, Li A, Leng Y, Li Y, Kang J. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA and Cell Biology. 2012 Apr 1;31(4):592-9.
13. Tao S, Sun J, Hao F, Tang W, Li X, Guo D, Liu X. Effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy. Journal of Stroke and Cerebrovascular Diseases. 2020 May 1;29(5):104644.
14. Gao, Q., Wang, Y., Ma, N., Dai, H., Roy, A.C., Chang, G., Shi, X. and Shen, X., 2020. Sodium valproate attenuates the iE-DAP induced inflammatory response by inhibiting the NOD1-NF-κB pathway and histone modifications in bovine mammary epithelial cells. International Immunopharmacology, 83, p.106392.
15. Chen S, Ye J, Chen X, Shi J, Wu W, Lin W, Lin W, Li Y, Fu H, Li S. Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3. Journal of neuroinflammation. 2018 Dec;15:1-4.
16. Liang KG, Mu RZ, Liu Y, Jiang D, Jia TT, Huang YJ. Increased serum S100B levels in patients with epilepsy: a systematic review and meta-analysis study. Frontiers in neuroscience. 2019 May 16;13:456.
17. Hafez AS, El-Sarnagawy GN. S-100β in predicting the need of hyperbaric oxygen in CO-induced delayed neurological sequels. Human & Sodium valproate erimental Toxicology. 2020 May;39(5):614-23.
18. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW, Cochrane Epilepsy Group. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews. 1996 Sep 1;2010(1).
19. Gómez CD, Buijs RM, Sitges M. The anti‐seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL‐1β and TNF‐α expression in rat hippocampus. Journal of neurochemistry. 2014 Sep;130(6):770-9.
20. Shehata GA, Bateh AE, Hamed SA, Rageh TA, Elsorogy YB. Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy. Neuropsychiatric disease and treatment. 2009 Nov 2:527-33.
21. G, Liang L, Chen X, Zhong G, Huang C, Lin P, Kuang Z. Therapeutic Impact of Serum Inflammatory Cytokines and S-100Β Levels in Patients With Acute Secondary Epilepsy Treated With Sodium Valproate. American Journal of Therapeutics. 2022 Sep 1:10-97.
22. Bayat M, Jalali N, Poursadeghfard M, Nazeri M, Dabbaghmanesh MH, Ashjazadeh N. Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study. Journal of Kerman University of Medical Sciences. 2021 Nov 1;28(6).
23. Tao S, Sun J, Hao F, Tang W, Li X, Guo D, Liu X. Effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy. Journal of Stroke and Cerebrovascular Diseases. 2020 May 1;29(5):104644.
24. Stakišaitis D, Kapočius L, Tatarūnas V, Gečys D, Mickienė A, Tamošuitis T, Ugenskienė R, Vaitkevičius A, Balnytė I, Lesauskaitė V. Effects of Combined Treatment with Sodium Dichloroacetate and Sodium Valproate on the Genes in Inflammation-and Immune-Related Pathways in T Lymphocytes from Patients with SARS-CoV-2 Infection with Pneumonia: Sex-Related Differences. Pharmaceutics. 2024 Mar 16;16(3):409.
Copyright (c) 2025 Xiao Lu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.